CLINICAL TRIALS PROFILE FOR THIABENDAZOLE
✉ Email this page to a colleague
All Clinical Trials for THIABENDAZOLE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02262299 ↗ | European Trial of Pirfenidone in BOS, A European Multi-center Study | Completed | Rigshospitalet, Denmark | Phase 2/Phase 3 | 2015-05-01 | A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. Randomized double blinded, placebo controlled study. Eligible patients are to be randomized in a 1:1 ratio to receive either Pirfenidone 2403 mg/d or the matching placebo treatment for 6 months. Primary objective To evaluate the effect of Pirfenidone on the change in FEV1 in liters over 6 months in lung transplant recipients with bronchiolitis obliterans syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for THIABENDAZOLE
Condition Name
Clinical Trial Locations for THIABENDAZOLE
Clinical Trial Progress for THIABENDAZOLE
Clinical Trial Phase
Clinical Trial Sponsors for THIABENDAZOLE
Sponsor Name